The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis

Asuka Yasueda, Tsunekazu Mizushima, Riichiro Nezu, Ryoko Sumi, Mamoru Tanaka, Junichi Nishimura, Yasuyuki Kai, Masaki Hirota, Hideki Osawa, Kiyokazu Nakajima, Masaki Mori, Toshinori Ito

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: Ulcerative colitis (UC) is a chronic, relapsing, and refractory disorder of the intestine. Total proctocolectomy with ileal pouch anal anastomosis (IPAA) is the preferred and standard surgical procedure for patients’ refractory to medical therapy. Pouchitis is one of the most common long-term complications after IPAA. In the present study, the safety and efficacy of Clostridium butyricum MIYAIRI (CBM) as a probiotic were examined. Methods: A randomized and placebo-controlled study was performed. Seventeen patients were recruited from 2007 to 2013. Nine tablets of MIYA-BM® or placebo were orally administered once daily. The cumulative pouchitis-free survival, pouch condition (using the modified pouch disease activity index), and blood parameters were evaluated. A fecal sample analysis was also performed. Results: Subjects were randomly allocated to receive MIYA-BM or placebo (9 and 8 subjects, respectively). One subject in the MIYA-BM group and four subjects in the placebo group developed pouchitis. No side effects occurred in either group. Characteristic intestinal flora was observed in each group. Conclusions: Our results suggest that probiotic therapy with CBM achieved favorable results with minimal side effects and might be a useful complementary therapy for the prevention of pouchitis in patients with UC who have undergone IPAA.

Original languageEnglish
Pages (from-to)939-949
Number of pages11
JournalSurgery today
Volume46
Issue number8
DOIs
Publication statusPublished - Aug 1 2016
Externally publishedYes

Fingerprint

Clostridium butyricum
Pouchitis
Microbiota
Ulcerative Colitis
Colonic Pouches
Placebos
Probiotics
Complementary Therapies
Tablets
Intestines
Safety
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. / Yasueda, Asuka; Mizushima, Tsunekazu; Nezu, Riichiro; Sumi, Ryoko; Tanaka, Mamoru; Nishimura, Junichi; Kai, Yasuyuki; Hirota, Masaki; Osawa, Hideki; Nakajima, Kiyokazu; Mori, Masaki; Ito, Toshinori.

In: Surgery today, Vol. 46, No. 8, 01.08.2016, p. 939-949.

Research output: Contribution to journalArticle

Yasueda, A, Mizushima, T, Nezu, R, Sumi, R, Tanaka, M, Nishimura, J, Kai, Y, Hirota, M, Osawa, H, Nakajima, K, Mori, M & Ito, T 2016, 'The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis', Surgery today, vol. 46, no. 8, pp. 939-949. https://doi.org/10.1007/s00595-015-1261-9
Yasueda, Asuka ; Mizushima, Tsunekazu ; Nezu, Riichiro ; Sumi, Ryoko ; Tanaka, Mamoru ; Nishimura, Junichi ; Kai, Yasuyuki ; Hirota, Masaki ; Osawa, Hideki ; Nakajima, Kiyokazu ; Mori, Masaki ; Ito, Toshinori. / The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. In: Surgery today. 2016 ; Vol. 46, No. 8. pp. 939-949.
@article{bb3925a7674d45af9029bffe023301d2,
title = "The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis",
abstract = "Purpose: Ulcerative colitis (UC) is a chronic, relapsing, and refractory disorder of the intestine. Total proctocolectomy with ileal pouch anal anastomosis (IPAA) is the preferred and standard surgical procedure for patients’ refractory to medical therapy. Pouchitis is one of the most common long-term complications after IPAA. In the present study, the safety and efficacy of Clostridium butyricum MIYAIRI (CBM) as a probiotic were examined. Methods: A randomized and placebo-controlled study was performed. Seventeen patients were recruited from 2007 to 2013. Nine tablets of MIYA-BM{\circledR} or placebo were orally administered once daily. The cumulative pouchitis-free survival, pouch condition (using the modified pouch disease activity index), and blood parameters were evaluated. A fecal sample analysis was also performed. Results: Subjects were randomly allocated to receive MIYA-BM or placebo (9 and 8 subjects, respectively). One subject in the MIYA-BM group and four subjects in the placebo group developed pouchitis. No side effects occurred in either group. Characteristic intestinal flora was observed in each group. Conclusions: Our results suggest that probiotic therapy with CBM achieved favorable results with minimal side effects and might be a useful complementary therapy for the prevention of pouchitis in patients with UC who have undergone IPAA.",
author = "Asuka Yasueda and Tsunekazu Mizushima and Riichiro Nezu and Ryoko Sumi and Mamoru Tanaka and Junichi Nishimura and Yasuyuki Kai and Masaki Hirota and Hideki Osawa and Kiyokazu Nakajima and Masaki Mori and Toshinori Ito",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00595-015-1261-9",
language = "English",
volume = "46",
pages = "939--949",
journal = "Surgery Today",
issn = "0941-1291",
publisher = "Springer Japan",
number = "8",

}

TY - JOUR

T1 - The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis

AU - Yasueda, Asuka

AU - Mizushima, Tsunekazu

AU - Nezu, Riichiro

AU - Sumi, Ryoko

AU - Tanaka, Mamoru

AU - Nishimura, Junichi

AU - Kai, Yasuyuki

AU - Hirota, Masaki

AU - Osawa, Hideki

AU - Nakajima, Kiyokazu

AU - Mori, Masaki

AU - Ito, Toshinori

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Purpose: Ulcerative colitis (UC) is a chronic, relapsing, and refractory disorder of the intestine. Total proctocolectomy with ileal pouch anal anastomosis (IPAA) is the preferred and standard surgical procedure for patients’ refractory to medical therapy. Pouchitis is one of the most common long-term complications after IPAA. In the present study, the safety and efficacy of Clostridium butyricum MIYAIRI (CBM) as a probiotic were examined. Methods: A randomized and placebo-controlled study was performed. Seventeen patients were recruited from 2007 to 2013. Nine tablets of MIYA-BM® or placebo were orally administered once daily. The cumulative pouchitis-free survival, pouch condition (using the modified pouch disease activity index), and blood parameters were evaluated. A fecal sample analysis was also performed. Results: Subjects were randomly allocated to receive MIYA-BM or placebo (9 and 8 subjects, respectively). One subject in the MIYA-BM group and four subjects in the placebo group developed pouchitis. No side effects occurred in either group. Characteristic intestinal flora was observed in each group. Conclusions: Our results suggest that probiotic therapy with CBM achieved favorable results with minimal side effects and might be a useful complementary therapy for the prevention of pouchitis in patients with UC who have undergone IPAA.

AB - Purpose: Ulcerative colitis (UC) is a chronic, relapsing, and refractory disorder of the intestine. Total proctocolectomy with ileal pouch anal anastomosis (IPAA) is the preferred and standard surgical procedure for patients’ refractory to medical therapy. Pouchitis is one of the most common long-term complications after IPAA. In the present study, the safety and efficacy of Clostridium butyricum MIYAIRI (CBM) as a probiotic were examined. Methods: A randomized and placebo-controlled study was performed. Seventeen patients were recruited from 2007 to 2013. Nine tablets of MIYA-BM® or placebo were orally administered once daily. The cumulative pouchitis-free survival, pouch condition (using the modified pouch disease activity index), and blood parameters were evaluated. A fecal sample analysis was also performed. Results: Subjects were randomly allocated to receive MIYA-BM or placebo (9 and 8 subjects, respectively). One subject in the MIYA-BM group and four subjects in the placebo group developed pouchitis. No side effects occurred in either group. Characteristic intestinal flora was observed in each group. Conclusions: Our results suggest that probiotic therapy with CBM achieved favorable results with minimal side effects and might be a useful complementary therapy for the prevention of pouchitis in patients with UC who have undergone IPAA.

UR - http://www.scopus.com/inward/record.url?scp=84945550161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945550161&partnerID=8YFLogxK

U2 - 10.1007/s00595-015-1261-9

DO - 10.1007/s00595-015-1261-9

M3 - Article

VL - 46

SP - 939

EP - 949

JO - Surgery Today

JF - Surgery Today

SN - 0941-1291

IS - 8

ER -